Allogene Therapeutics, Inc.
ALLO
$1.77
-$0.09-4.84%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -165.49M | -173.76M | -190.89M | -212.02M | -236.91M |
| Total Depreciation and Amortization | 11.67M | 12.13M | 12.36M | 12.54M | 12.65M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 33.14M | 36.61M | 40.16M | 46.54M | 62.78M |
| Change in Net Operating Assets | 18.49M | 15.79M | -10.88M | -5.41M | -11.29M |
| Cash from Operations | -102.20M | -109.23M | -149.25M | -158.35M | -172.77M |
| Capital Expenditure | -402.00K | -296.00K | -386.00K | -643.00K | -829.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -131.20M | 60.09M | 95.95M | 117.52M | 29.78M |
| Cash from Investing | -131.60M | 59.80M | 95.56M | 116.88M | 28.95M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 220.09M | 33.73M | 23.25M | 21.13M | 18.58M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 3.56M | 6.91M | 6.91M | 6.91M |
| Cash from Financing | 220.09M | 37.29M | 30.16M | 28.04M | 25.48M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -13.71M | -12.15M | -23.53M | -13.42M | -118.34M |